Department of Pharmacology, M.R. Medical College, Sedam Road, Gulbarga - 585 105, India.
Indian J Pharmacol. 2009 Oct;41(5):218-20. doi: 10.4103/0253-7613.58510.
Clonidine, a known antihypertensive, is currently used for many purposes including diabetic gastroparesis, postmenopausal hot flushes, opioid/nicotine/alcohol withdrawal. Its effects on carbohydrate metabolism appear to be variable. Hence, the present study was undertaken to evaluate the influence of clonidine on euglycemic and alloxan -induced diabetic rats and its interaction with glibenclamide.
Alloxan - induced (150 mg/kg, i.p) diabetic rats were divided into six groups of six animals each. Group I - Normal Control; Group II - Nondiabetic + Clonidine (25 mug/kg); Group III - Diabetic Control; Group IV - Diabetic + Glibenclamide (5 mg/kg); Group V - Diabetic + Glibenclamide + Clonidine. All drugs were given orally once daily. Blood glucose was estimated from rat tail vein using glucometer before start of the experiment and at the end of 30 days.
After 30 days of treatment, clonidine (25 mug/kg) produced significant hyperglycemia in both euglycemic and diabetic rats. It also reduced the hypoglycemic effect of glibenclamide in diabetic rats.
The results of present study indicate that clonidine has hyperglycemic effect and it also interacts with glibenclamide to reduce its hypoglycemic activity. If these findings are true to human beings then clonidine should not be used in diabetic patients on sulfonylureas.
可乐定是一种已知的降压药，目前被用于多种用途，包括糖尿病性胃轻瘫、绝经后热潮红、阿片类药物/尼古丁/酒精戒断。它对碳水化合物代谢的影响似乎是可变的。因此，本研究旨在评估可乐定对正常血糖和四氧嘧啶诱导的糖尿病大鼠的影响及其与格列本脲的相互作用。
将四氧嘧啶（150mg/kg，ip）诱导的糖尿病大鼠分为 6 组，每组 6 只。组 I-正常对照；组 II-非糖尿病+可乐定（25μg/kg）；组 III-糖尿病对照；组 IV-糖尿病+格列本脲（5mg/kg）；组 V-糖尿病+格列本脲+可乐定。所有药物均每天口服一次。在实验开始前和 30 天后，使用血糖仪从大鼠尾静脉估计血糖。
治疗 30 天后，可乐定（25μg/kg）在正常血糖和糖尿病大鼠中均产生显著的高血糖。它还降低了格列本脲在糖尿病大鼠中的降血糖作用。
本研究的结果表明，可乐定具有升高血糖的作用，它还与格列本脲相互作用，降低其降血糖活性。如果这些发现对人类是真实的，那么糖尿病患者就不应该使用磺酰脲类药物。
